Logo

TELA

TELA Bio, Inc.

TELA

TELA Bio, Inc. • NASDAQ
$1.15 ▲ 2.68% (+0.03)
Market Cap $46.36 M
52w High $3.20
52w Low $0.86
Dividend Yield 0%
P/E -1.39
Volume 774.62K
Outstanding Shares 40.32M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $20.689M ▲ $21.523M ▼ $-8.603M ▲ -41.582% ▲ $-0.19 ▲ $-7.154M ▲
Q2-2025 $20.197M ▲ $23.186M ▲ $-9.923M ▲ -49.131% ▲ $-0.22 ▲ $-8.432M ▲
Q1-2025 $18.52M ▲ $22.984M ▲ $-11.264M ▼ -60.821% ▼ $-0.25 ▼ $-9.726M ▼
Q4-2024 $17.649M ▼ $19.575M ▼ $-9.208M ▲ -52.173% ▲ $-0.23 ▲ $-7.803M ▲
Q3-2024 $18.957M $22.223M $-10.372M -54.713% $-0.42 $-8.765M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $29.713M ▼ $61.587M ▼ $60.03M ▲ $1.557M ▼
Q2-2025 $34.977M ▼ $67.537M ▼ $58.353M ▼ $9.184M ▼
Q1-2025 $42.833M ▼ $77.251M ▼ $59.128M ▲ $18.123M ▼
Q4-2024 $52.67M ▲ $87.326M ▲ $58.868M ▼ $28.458M ▲
Q3-2024 $17.301M $53.016M $59.288M $-6.272M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-8.603M ▲ $-5.719M ▲ $312K ▲ $24K ▲ $-5.264M ▲ $-5.93M ▲
Q2-2025 $-9.923M ▲ $-7.905M ▲ $204K ▲ $-3K ▲ $-7.856M ▲ $-8.019M ▲
Q1-2025 $-11.264M ▼ $-9.725M ▼ $138K ▲ $-116K ▼ $-9.837M ▼ $-9.757M ▼
Q4-2024 $-9.208M ▲ $-7.531M ▲ $-190K ▼ $42.908M ▲ $35.369M ▲ $-7.795M ▲
Q3-2024 $-10.372M $-8.983M $-122K $98K $-9.195M $-9.105M

Five-Year Company Overview

Income Statement

Income Statement TELA Bio’s sales have been climbing steadily over the past several years, and its core product line appears to be gaining traction. The company consistently earns a positive gross profit on what it sells, which suggests its products are priced and produced in a way that can support a viable business model at scale. However, the company is still firmly in the “investment” phase. Operating losses and net losses remain meaningful each year. While the loss per share has generally been moving in the right direction over time, the business is not yet close to break-even. Profitability will depend on how quickly revenue can continue to grow relative to sales, marketing, and R&D spending.

Balance Sheet

Balance Sheet TELA Bio’s balance sheet shows a lean but fairly straightforward structure. Assets have grown modestly, with cash making up a large share of total assets. This reflects a typical profile for a small, commercial-stage medical device company that is not very capital-intensive. Debt levels are present but not extreme, and they have stayed relatively stable over the last few years. Equity declined notably earlier in the period and then started to rebuild, which suggests past losses have weighed on the balance sheet but new capital and growth have partially offset that. Overall, the company appears adequately resourced for its size, but the equity base is still thin, making it sensitive to ongoing losses and any future funding needs.

Cash Flow

Cash Flow TELA Bio is consistently using, rather than generating, cash from its operations. The company’s cash outflows from day-to-day business activities have been fairly steady over the years, reflecting ongoing investments in sales, marketing, and clinical and product development. Because capital spending is minimal, free cash flow essentially mirrors operating cash flow and is also negative. This means the company depends on its existing cash reserves and periodic external financing to fund growth and cover losses. The central cash-flow question is how quickly revenue can scale relative to spending before additional capital is needed.

Competitive Edge

Competitive Edge TELA Bio operates in a focused niche within the broader surgical mesh and soft tissue reconstruction market. Its main differentiation comes from the OviTex platform, which blends biologic and synthetic materials to address some of the shortcomings of traditional meshes. This gives the company a clear story to tell surgeons who are looking for alternatives to purely synthetic or purely biologic options. The company has several important strengths: proprietary technology backed by patents, growing clinical data, and close relationships with surgeons helped by a direct-sales and education-focused approach. The acquisition of TIGR Matrix broadens the portfolio and gives it more ways to address different surgical needs. On the other hand, TELA Bio is still a small player in a space dominated by large, established medical device companies with deep commercial and financial resources. Its success will depend on continued surgeon adoption, hospital acceptance, reimbursement dynamics, and its ability to maintain differentiation as competitors respond.

Innovation and R&D

Innovation and R&D Innovation is a core part of TELA Bio’s identity. The OviTex platform itself is a notable technical step away from traditional mesh designs, and the company continues to refine it with new product sizes, formats, and use cases, including offerings aimed at robotic and minimally invasive surgery. TELA Bio’s R&D focus is practical and market-driven: improving how easily surgeons can handle the product, enhancing tissue integration, and extending how long materials provide support before they are absorbed. The acquisition of TIGR Matrix adds another technology track, giving the company a broader innovation platform in soft tissue repair. The flip side is that this level of R&D and clinical work is costly and contributes to ongoing losses. Regulatory requirements and the need for strong clinical evidence add time and uncertainty to the payback on these investments. Still, the company’s innovation engine is a clear strategic asset if it can be matched with disciplined commercialization.

Summary

TELA Bio is a young, commercial-stage medical device company with a clear niche and an innovative product platform in soft tissue reconstruction. Revenue has been growing at a healthy pace, and product economics at the gross profit level look encouraging, but the company remains meaningfully loss-making and cash-consuming. The balance sheet and cash position are reasonable for a company of its size, but not yet robust enough to comfortably absorb prolonged heavy losses without future financing. The company’s differentiated technology, supportive clinical data, and surgeon-focused commercial model create a promising competitive position, albeit against much larger incumbents. Overall, this is a story of a specialized innovator that appears to be gaining traction but is still in the scale-up phase. The key variables to monitor are continued revenue growth, progress toward narrowing losses, cash usage, and the company’s ability to sustain its innovation advantage while managing the financial demands of commercialization and clinical development.

NEWS

November 19, 2025 · 8:30 AM UTC

TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

Read more

November 17, 2025 · 4:05 PM UTC

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more

November 13, 2025 · 4:21 PM UTC

TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants

Read more

November 13, 2025 · 4:01 PM UTC

TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility

Read more

October 9, 2025 · 4:05 PM UTC

TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran

Read more